Clinical Trials Logo

Clinical Trial Summary

This retrospective study aims to investigate whether initial imaging characteristics of rectal cancer on Magnetic Resonance Imaging (MRI) correlate with the underlying tumour pathology and oncological outcomes such as response to treatment. Using radiomic features, calculated using new high throughput analysis of previously acquired imaging, a statistically robust prognostic model will be created with the overall aim of developing imaging biomarkers.


Clinical Trial Description

Background Bowel cancer is the 4th most common type of cancer in the UK with 14,000 individuals diagnosed with rectal cancer each year. The management of rectal cancer has significantly changed in the last decade with the advent of individualised treatment tailored to the individual patient's pathology and disease burden. Both local control and overall survival in this group of patients are significantly linked with achieving a complete resection with clear circumferential resection margin (CRM). Radiology is essential to the patient pathway with Magnetic Resonance Imaging (MRI) used in the pre-operative staging process to evaluate not only whether the CRM is potentially involved (tumour or affected lymph node within 1-2mm from CRM), but also other adverse features such as extra mural vascular invasion (EMVI). With the increasing use of neo-adjuvant chemoradiation therapy (nCRT) the true heterogeneous nature of rectal cancer has become apparent: Rectal cancer patients with similar initial staging have significantly different responses to treatments. MRI can accurately delineate tumour burden; however, it fails to fully take account for this heterogeneity and it is still lacking in adequately evaluating CRM and lymph nodes status. It is only through imaging that the entirety of a rectal tumour is visualised prior to the commencement of treatment. An objective radiological tool that could accurately identify patients who are likely to achieve a complete response to nCRT followed by surgery would have a significant impact in clinical practice by allowing the selection of ideal candidates for organ-sparing strategies. Recent advances in image acquisition and image analysis that produce quantitative imaging descriptors could potentially play a significant role in bridging this unmet clinical need. The emerging field of Radiomics, uses quantitative data obtained from digital medical images, to extract uncovered mixed biological information. Radiomics is a technique that utilizes all the information available in an image via image processing software. Imaging studies become more than just pictures to be interpreted, instead the wealth of non-visual information generated by computers is used for greater understanding of disease. Within radiomics the numerical data which forms the basis of the images is extracted from a region of interest and analysed producing what is known as radiomics variables. The variables produced are vast and broadly represent the inter and intra-variability between these numerical values. Through the correlation/comparison of these variables with the pathology, genetics and treatment responses the investigators hypothesize that these imaging features (radiomics variables) capture the heterogeneity of rectal cancer. Identifying distinct phenotypic differences of tumours, which are not possible to depict by standard measurements and may have a predictive power and thus clinical significance across different diseases. This technique has been successfully applied in lung and head and neck cancers showing the translational potential of radiomics into clinical practice. The radiomics variables that can be extracted are divided into primary, second order/texture features and higher order characteristics. Primary characteristics reflect the variables related to the numerical data when assessed alone and includes mean, kurtosis and skewness, predominantly the histogram based characteristics. These do not account for the inter or intratumour heterogeneity as are not representative of the relationship between the voxels. It is secondary order characteristics that reflect how the individual pixels relate to the each other, measuring the intratumoural variability. These variables include fractional analyses and wavelets. Higher order characteristics identify and extract patterns within the region of interest in this case the rectal tumour. Higher order statistics include fractional dimensions and kaplacian transformations. These are a reflection of entire tumours characteristics and the identification of homogeneity within these higher order statistics within population subsets may reveal further information about the underlying tumours biology. Here, the investigators aim to assess the clinical relevance of radiomics variables in rectal cancer in order to improve the tumour assessment of this group of patients. It will facilitate more informed and personalized treatment decisions as to whether the patient should receive: new treatment versus conventional treatment or vice versa. Within rectal cancer this has the potential to develop and strengthen the role of radiology in recognizing new imaging biomarkers by radiomics. To date there are only a handful of studies applying radiomics in rectal cancer. Radiomics measurements performed separately using MRI data and recently explored using [18]-FDG-PET/CT data have shown interesting and significant results. However, very small sample sizes have been used and further investigations are needed. This study aims to address this need. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05331040
Study type Observational
Source NHS Grampian
Contact
Status Active, not recruiting
Phase
Start date May 1, 2020
Completion date May 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1